Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Maintenance dosing information for ILARIS in the treatment of FMF, HIDS/MKD, TRAPS and CAPS.

ILARIS® (canakinumab) has a convenient 4-weekly maintenance dosing schedule1


Ilaris TRAPS flow chart

In familial Mediterranean fever (FMF), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS), ILARIS is administered as a subcutaneous injection once every 4 weeks.1


 

ILARIS has a convenient 8-weekly maintenance dosing schedule, and patients are able to receive treatment at home1


Ilaris CAPS flow chart

 

In cryopyrin-associated periodic syndromes (CAPS), ILARIS is administered as a subcutaneous injection once every 8 weeks.1

 


 

Indications

ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • TRAPS
  • HIDS/MKD
  • FMF
    • ILARIS should be given in combination with colchicine, if appropriate.

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

Reference

  1. ILARIS® (canakinumab) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | November 2021 | 160458
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]